Cargando…
Multi-biomarker is an early-stage predictor for progression of Coronavirus disease 2019 (COVID-19) infection
Coronavirus disease 2019 (COVID-19) has spread widely in the communities in many countries. Although most of the mild patients could be cured by their body's ability to self-heal, many patients quickly progressed to severe disease and had to undergo treatment in the intensive care unit (ICU). T...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241766/ https://www.ncbi.nlm.nih.gov/pubmed/34220307 http://dx.doi.org/10.7150/ijms.58742 |
_version_ | 1783715483158052864 |
---|---|
author | Zhou, Zheng Li, Ying Ma, Yuanhui Zhang, Heng Deng, Yunfeng Zhu, Zuobin |
author_facet | Zhou, Zheng Li, Ying Ma, Yuanhui Zhang, Heng Deng, Yunfeng Zhu, Zuobin |
author_sort | Zhou, Zheng |
collection | PubMed |
description | Coronavirus disease 2019 (COVID-19) has spread widely in the communities in many countries. Although most of the mild patients could be cured by their body's ability to self-heal, many patients quickly progressed to severe disease and had to undergo treatment in the intensive care unit (ICU). Thus, it is very important to effectively predict which patients with mild disease are more likely to progress to severe disease. A total of 72 patients hospitalized with COVID-19 in Shandong Provincial Public Health Clinical Center and 1141 patients included in the published papers were enrolled in this study. We determined that the combination of interleukin-6 (IL-6), Neutrophil (NEUT), and Natural Killer (NK) cells had the highest prediction accuracy (with 75% sensitivity and 95% specificity) for progression of COVID-19 infection. A binomial regression equation that accounted for a multiple risk score for the combination of IL-6, NEUT, and NK was also established. The multiple risk score is a good indicator for early stratification of mild patients into risk categories, which is very important for adjusting the treatment plan and preventing death. |
format | Online Article Text |
id | pubmed-8241766 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-82417662021-07-01 Multi-biomarker is an early-stage predictor for progression of Coronavirus disease 2019 (COVID-19) infection Zhou, Zheng Li, Ying Ma, Yuanhui Zhang, Heng Deng, Yunfeng Zhu, Zuobin Int J Med Sci Research Paper Coronavirus disease 2019 (COVID-19) has spread widely in the communities in many countries. Although most of the mild patients could be cured by their body's ability to self-heal, many patients quickly progressed to severe disease and had to undergo treatment in the intensive care unit (ICU). Thus, it is very important to effectively predict which patients with mild disease are more likely to progress to severe disease. A total of 72 patients hospitalized with COVID-19 in Shandong Provincial Public Health Clinical Center and 1141 patients included in the published papers were enrolled in this study. We determined that the combination of interleukin-6 (IL-6), Neutrophil (NEUT), and Natural Killer (NK) cells had the highest prediction accuracy (with 75% sensitivity and 95% specificity) for progression of COVID-19 infection. A binomial regression equation that accounted for a multiple risk score for the combination of IL-6, NEUT, and NK was also established. The multiple risk score is a good indicator for early stratification of mild patients into risk categories, which is very important for adjusting the treatment plan and preventing death. Ivyspring International Publisher 2021-05-27 /pmc/articles/PMC8241766/ /pubmed/34220307 http://dx.doi.org/10.7150/ijms.58742 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Zhou, Zheng Li, Ying Ma, Yuanhui Zhang, Heng Deng, Yunfeng Zhu, Zuobin Multi-biomarker is an early-stage predictor for progression of Coronavirus disease 2019 (COVID-19) infection |
title | Multi-biomarker is an early-stage predictor for progression of Coronavirus disease 2019 (COVID-19) infection |
title_full | Multi-biomarker is an early-stage predictor for progression of Coronavirus disease 2019 (COVID-19) infection |
title_fullStr | Multi-biomarker is an early-stage predictor for progression of Coronavirus disease 2019 (COVID-19) infection |
title_full_unstemmed | Multi-biomarker is an early-stage predictor for progression of Coronavirus disease 2019 (COVID-19) infection |
title_short | Multi-biomarker is an early-stage predictor for progression of Coronavirus disease 2019 (COVID-19) infection |
title_sort | multi-biomarker is an early-stage predictor for progression of coronavirus disease 2019 (covid-19) infection |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241766/ https://www.ncbi.nlm.nih.gov/pubmed/34220307 http://dx.doi.org/10.7150/ijms.58742 |
work_keys_str_mv | AT zhouzheng multibiomarkerisanearlystagepredictorforprogressionofcoronavirusdisease2019covid19infection AT liying multibiomarkerisanearlystagepredictorforprogressionofcoronavirusdisease2019covid19infection AT mayuanhui multibiomarkerisanearlystagepredictorforprogressionofcoronavirusdisease2019covid19infection AT zhangheng multibiomarkerisanearlystagepredictorforprogressionofcoronavirusdisease2019covid19infection AT dengyunfeng multibiomarkerisanearlystagepredictorforprogressionofcoronavirusdisease2019covid19infection AT zhuzuobin multibiomarkerisanearlystagepredictorforprogressionofcoronavirusdisease2019covid19infection |